The association between mRNA expression of resistin, TNF-α, IL-6, IL-8, and ER-α in peripheral blood mononuclear cells and breast cancer

Maasoumeh ZARE MOAIEDI1, Fatemeh AHMADPOOR1, Mojtaba RASHIDI1, Ahmad AHMADZADEH1,2, Amir Ahmad SALMASI1,3, Ghorban MOHAMMADZADEH1,4*

1Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2Department of Hematology-Oncology, Faculty of Medicine, Firoozgar Clinical Research Development Center, Iran University of Medical Sciences, Tehran, Iran
3Department of Surgery, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Science, Hyperlipidemia Research center, Ahvaz, Iran

* Correspondence: mohammadzadeh@ajums.ac.ir

1.Introduction
Breast cancer, the most common malignancy in women worldwide, recently, considered a major global health burden in all nations [1]. Previously, a considerable and potential role of adipokines in the development of breast cancer has been suggested [2]. Resistin, a 12.5 kDa peptide, was first detected in mouse adipocytes where has been associated with insulin resistance and the development of type 2 diabetes [3]. Several studies found that human serum resistin was associated with different cancers including breast, prostatic, colorectal, and endometrial cancers [4-7].

Tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine, was originally identified in adipose-tissue infiltrated-macrophages, and its serum concentration was positively associated with body mass index (BMI) [8]. In overweight and obese individuals clinical trials, it has been reported that an increased level of TNF-α expression was associated with the increased risk of breast cancer [9].

Interleukin-6 (IL-6), a pleiotropic cytokine, was originally produced by different cell types such as endothelial and normal hematopoietic cells [10]. It is an effective pleiotropic cytokine that is considered a key growth-promoting and anti-apoptotic factor [11]. In breast tumors, the major sources of IL-6 are including tumor-derived fibroblasts, and tumor-infiltrated macrophages and lymphocytes [12]. However, IL-6 activity in cancer
has not been completely understood, and its controversial roles in both tumorigenesis and tumor suppression have been reported [13].

Interleukin 8 (IL-8), well-known as a chemotactic cytokine, is the main factor for the recruitment of neutrophils and causes the initiation of an inflammatory response [14]. Several studies demonstrated that the expression of IL-8 increased in several human tumors [15,16] and was usually accompanied by malignancy [17]. The effect of IL-8 on the migration and invasion of tumor cells is vital for the development and cancer metastasis [18]. Some studies have been demonstrated that monocytes, T cells, and B cells could respond to estrogens, and the increased level of estrogen receptor alpha (ER-α) and estrogen receptor beta (ER-β) expression in these cells have been reported [19,20]. We investigated whether the mRNA expression of resistin, TNF-α, IL-6, IL-8, and ER-α in PBMCs are associated with breast cancer.

2. Materials and methods

2.1. Study populations

The study population that participated in the current research was 40 Iranian females. Breast cancer patients (n = 32) were attended at Ahvaz Golestan Hospital, Ahvaz, Iran, from January 2018 till November 2019. Of the 32 women diagnosed with cancer, 16 women were new cases without any treatment, 8 women were recruited before receiving initial adjuvant chemotherapy (chemotherapy after surgery), and 8 women were recruited before receiving neoadjuvant chemotherapy (chemotherapy before surgery). Blood samples were obtained before the participants’ first chemotherapy. Adjuvant chemotherapy patients were those who were at least in their 4th-week postsurgery (lumpectomy or mastectomy). The clinical diagnosis of breast cancer was confirmed by the histopathological examination of the tumor tissue samples. Hormone receptor status was checked according to the medical records with cytopathology or immunohistochemistry. Demographic characteristics including age, height, weight, and BMI were measured by the same physician under similar conditions at the same time. Breast cancer patients were further divided into two subgroups: those without surgery (n = 16) were new cases and confirmed from the sample obtained by biopsy, and those with surgery who were diagnosed and confirmed with histopathological examination of the tumor tissue samples. Healthy control individuals (n = 18) were age and BMI matched to breast cancer patients. The healthy control group was randomly selected from the Outpatient Clinic of Internal Medicine at the same hospital among women who came for an annual check-up examination and given a negative mammogram result showing the absence of breast cancer and other malignant breast diseases. All subjects enrolled in the current study were Iranians with the ancestry of Khuzestan Province, southwest of Iran, and all of them gave written informed consent. The study protocol was approved by the Ethics Committee of the Ahvaz Jundishapur University of Medical Sciences (IR. AJUMS.MEDICINE.REC.1398.005).

2.2. Sampling and PBMCs isolation

The venous blood sample was collected from preoperative patients before starting treatment. Another set of blood samples was also collected from 18 healthy control women. The density gradient centrifugation by Ficoll-Paque (Pharmacia, Freiburg, Germany) was used for PBMCs isolation. First, 3.5 mL of Ficoll was transferred into a centrifugation tube. Then, anticoagulated blood samples were diluted with a 1:1 ratio with phosphate-buffered saline (PBS, pH = 7.4), and cautiously pipetted over a Ficoll-Paque gradient (7 mL/tube). The samples were centrifuged at 600 × g for 20 min at room temperature. The PBMCs containing layer was removed and the cells were washed two times with PBS, pH = 7.4. Finally, the isolated PBMCs were stored at −80°C until used for RNA isolation.

2.3. RNA extraction, cDNA synthesis and real-time polymerase chain reaction (PCR) analysis

Total RNA was extracted from PBMCs using Favor Pre Total RNA mini kit (Favorgen Biotech Corp. Wembley, Australia). The concentration of RNA was determined by colorimetric assay at 260 nm, whereas the purity of RNA was determined by calculating the A260/280 nm ratio. The integrity of RNA was evaluated on 1% agarose gel electrophoresis with visualization of 18S and 28S rRNA bands. The complementary DNA (cDNA) was synthesized based on the Yakta Tajhiz Azma (YTA) cDNA synthesis kit (Cat No. YT 4500, Tehran, Iran). The mRNA expression was measured by ABI Step One Plus real-time PCR (Applied Biosystems, USA), using RealQ Plus 2× Master Mix Green High RO (Amplicon, Odense, Denmark) with specific primers for target genes (resistin, TNF-α, IL-6, IL-8, and ER-α), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control. Relative expression software tool (REST, 2009 v2.0.13) was used for analysis based on the 2^ΔΔCt method. The specific primers for target genes were designed using Primer-Blast by The National Center for Biotechnology Information (NCBI) as shown in Table 1. The size and specificity of PCR products were determined by standard electrophoresis on a 1% agarose gel containing safe stain and melting curve analysis, respectively, as shown in Figure 1.

2.4. Statistical analysis

Statistical analysis of the data was performed using a commercially available IBM Statistical Package for the Social Sciences (SPSS, Chicago, IL, USA) software. Quantitative data were presented as mean ± standard deviation (SD). The normal distribution of data was
assessed by the Kolmogorov–Smirnov test. The comparison of normal distributed quantitative data between groups was done using ANOVA following Post hoc pairwise comparison Tukey test. For comparison of data that didn't have normal distribution, the Kruskal–Wallis and Mann–Whitney U test was used. The association between gene expression and breast cancer was determined using logistic regression analysis, and the results are presented as the odds ratio (OR) [95% confidence intervals (CIs)]. Receiver operator characteristic (ROC) curve analysis and calculation of the area under the ROC curve (AUC) were carried out to assess the power of target genes in PBMCs to properly discriminate between breast cancer patients and controls. A two-sided P value of less than 0.05 was considered significant for all tests.

### 3. Results

#### 3.1. Demographic and clinicopathological characteristics of the subjects

A total of 32 women with breast cancer were identified (median age, 45; range, 28–60 years), and 18 women without breast cancer were identified as healthy control (median age, 42; range, 36–53 years). Breast cancer patients were not significantly different from healthy controls in terms of age and BMI. Breast cancer patients were further divided into two subgroups based on with and without surgery. The results of cytopathology analysis for hormone-responsiveness biomarkers among 16 breast cancer patients without sugary indicated 12 (75 %) patients were estrogen (ER)-positive, 13 (81.3%) patients with progesterone (PR)-positive, and 4 (25%) patients with HER2-positive; whereas, among 16 breast cancer patients with surgery, 13 (81.3%) patients were estrogen (ER)-positive, 10 (62.5) % patients were progesterone (PR)-positive, and 4 (25%) patients were HER2-positive (Table 2).

| Genes   | Primer length | Sequence (5’ →3’)                  | PCR Product length (bp) |
|---------|---------------|------------------------------------|-------------------------|
| GAPDH   | 21            | F-GTCTGGAAGTCAACGGATTGG            | 194                     |
| GAPDH   | 21            | R-TAGTACAAGCTTCGGTCTT             |                         |
| Resistin| 18            | F-TACTTGCCGCCGAGGCTT              | 119                     |
| Resistin| 18            | R-GTCGGTGACTGTCCTGATT             |                         |
| TNF-α   | 21            | F-CCATATGTTAGCAACCCTC             | 102                     |
| TNF-α   | 22            | R-GTCGTTATCTGTGCTCCAC            |                         |
| IL-6    | 20            | F-CATCCTCGACGGCACTCAG             | 164                     |
| IL-6    | 20            | R-TCACCAGGGACGTCTCCTCA            |                         |
| IL-8    | 20            | F-CTTGGGAGGCGCTTCCTGATT          | 68                      |
| IL-8    | 24            | R-TCTTCTAGCACTCCTGGCAAAAC        |                         |
| ER-α    | 20            | F-GGTGGCCCTACTACCGAGGA           | 85                      |
| ER-α    | 24            | R-ATCTGAAATTGCGCTGTAATGC         |                         |

GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; TNF-α: Tumornecrosis factor-alpha; IL-6: Interleukin 6, IL-8: Interleukin 8; ER-α: Estrogen receptor alpha; F: Forward; R: Reverse.
whereas, breast cancer patients with surgery indicated the frequencies of 4 (25%), 50% (8), and 25% (4), respectively for grade I, II, and III (Table 2).

### 3.2. The mRNA expression of target genes in PBMCs

The mRNA expression of target genes was measured in the freshly ready RNA from PBMCs. Data are presented as fold change of gene expression measured in samples of breast cancer patients with and without surgery in comparison to controls (considered as a reference with fold expression = 1).

The mRNA expression of resistin was significantly high in patients without surgery in comparison to controls (p = 0.03). However, its mRNA expression was low in patients with surgery in comparison to controls, but not significant (p > 0.05) (Figure 2). Moreover, the mRNA expression of IL-6 was significantly high in patients without surgery in comparison to controls (p = 0.012). However, its mRNA expression was low in patients with surgery in comparison to controls, but not significant (p > 0.05) (Figure 3). On the other hand, its mRNA expression was significantly low in patients with lumpectomy subgroup in comparison to patients without surgery (data not shown here).

The mRNA expression of TNF-α was high in patients without surgery in comparison to controls, but not significant (p > 0.05), whereas, its mRNA expression was low in patients with surgery in comparison to controls, but not significant (P > 0.05) (Figure 4). Also, our results indicated the mRNA expression of IL-8 was high in patients with and without surgery in comparison to controls, but not significant (p > 0.05) (Figures 5). Finally, the mRNA expression of ER-α was high in breast cancer patients without surgery in comparison to healthy controls, but not significant (Figure 6). However, its mRNA expression was significantly low in patients with mastectomy subgroup in comparison to patients without surgery (data not shown here).

Although, the mRNA expression of resistin in PBMCs of the population was not significantly associated with age (r = 0.228; p = 0.147) and BMI (r = -0.280; p = 0.165). However, the mRNA expression of resistin in PBMCs was significantly associated with the mRNA expression of IL-6 (0.412; p = 0.010), IL-8 (0.438; 0.011), TNF-α (0.490; p = 0.001), and ER-α (0.696; p < 0.001), respectively (data not shown here). Furthermore, logistic regression analysis indicated that none of the studied biomarkers were significantly associated with breast cancer (Table 3). Although, resistin’s diagnostic performance was not significant based on ROC curve analysis [0.680, 95% CI: 0.470–0.890, p = 0.110], the diagnostic performance of IL-6 was significant based on ROC curve analysis [0.825, 95% CI: 0.728–0.922, p < 0.001].

### Table 2. Characteristics of breast cancer patients.

| Variable        | Number | %    |
|-----------------|--------|------|
| Age             |        |      |
| ≤ 45            | 17     | 53.1 |
| ≥ 45            | 15     | 46.9 |
| Tumor type      |        |      |
| IDC             | 24     | 75.0 |
| ILC             | 8      | 25.0 |
| Histological grade |      |      |
| Low (I)         | 13     | 40.6 |
| High (II/III)   | 19     | 59.4 |
| ER              |        |      |
| +               | 25     | 78.1 |
| -               | 7      | 21.9 |
| PR              |        |      |
| +               | 23     | 71.9 |
| -               | 9      | 28.1 |
| HER2            |        |      |
| +               | 8      | 25.0 |
| -               | 24     | 75.0 |

IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; Grade I: well-differentiated tumor; Grade II: Moderately differentiated tumor; Grade III: poorly differentiated tumor; ER: estrogen receptor; PR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2.
95% CI: 0.549–0.947, p = 0.030); thus, IL-6 might be considered as a breast cancer biomarker that reflecting an early and inflammatory stage of the disease (Table 4).

4. Discussion
High expression and increased serum level of harmful pro-inflammatory cytokines including resistin, TNF-α, IL-6, and IL-8 are associated with shorter survival and poor prognosis of breast cancer [2-5]. The use of tumor tissue samples for the analysis of gene expression has been reported in clinical practice [21]. Other studies showed that PBMCs can be used to develop gene expression-based tests for early detection of breast cancer and as a biomarker for identifying solid tumors at an early stage [22,23]. Generally, PBMCs are a valuable source of biomarkers in clinical and experimental studies because they can easily be obtained from patients and are readily available. To the best of our knowledge, there is no report regarding the association between resistin, TNF-α, IL-6, IL-8, and ER-α expression in PBMCs and breast cancer. We have demonstrated that the mRNA expression of resistin and IL-6 in PBMCs of women with breast cancer was significantly high in comparison to women without breast cancer.

Resistin, TNFα, IL-6, and IL-8 are major pro-inflammatory cytokines that are involved in systemic inflammation and acute-phase reactions. These cytokines have also been demonstrated that associated with the development of breast cancer [24]. Chronic inflammation not only has a major role in the development of cancer but also considered a condition that reflects the early pathologic changes in mammary cells and can be associated with the risk of breast cancer development [25,26]. A previous study has been demonstrated that resistin was highly expressed in serum and tumor tissue samples of patients with breast cancer [7]. Moreover, some studies found that the higher serum level of resistin was directly associated with more clinicopathological characteristics including tumor grade, tumor size, lymph node metastasis, inflammation, and metabolism. They suggested that resistin may be considered as a biomarker for the diagnosis and monitoring of endocrine therapy in patients with breast cancer [7,24].

Our results indicated that the mRNA expression of IL-6 significantly increased in PBMCs of breast cancer patients especially in patients without surgery in comparison to those with surgery and healthy controls. IL-6 and TNFα are two major cytokines that could involve in systemic inflammation and acute-phase reactions; also, their serum
levels have been shown to increase in obese individuals and are consistently associated with the development of breast cancer [24,13]. Previous studies indicated that a high serum level of IL-6 and its soluble receptor has an independent prognostic value, and is associated with the extent and tumor grade of breast cancer [13,27]. We found that the mRNA expression of IL-6 significantly decreased in the patient with surgery in comparison to patients without surgery, which was also proved by the previous studies that showed serum level of IL-6 significantly decreased in patients after chemotherapy [28,29]. There is no report regarding the effect of surgery on the mRNA expression of IL-6; thus, we speculated that chemotherapy after surgery causes a reduction of IL-6 mRNA expression. Yokoe et al. in a study found that IL-6 level can be a predictive marker for recurrence of breast cancer [30]. On the other hand, IL-6 has been demonstrated to enhance breast cancer resistance to chemotherapy [31]; thus, targeting IL-6 could increase breast cancer sensitivity to chemotherapy [32]. Taken together, IL-6 not only has the potential to be a valuable predictive biomarker but also is a vital target for breast cancer treatment.

We found that the mRNA expression of TNF-α in PBMCs of breast cancer patients was higher than in control but not significant. However, its expression in patients with surgery (mastectomy) significantly decreased in comparison to those without surgery (data not shown here), which is consistent with the study conducted by Jablonska et al. [33] who found that TNF-α level decreased after chemotherapy. We didn't find any report regarding the association between surgery and TNF-α mRNA expression. Thus, we proposed that chemotherapy after mastectomy causes a reduction of its expression. TNF-α

Table 3. The association between resistin, TNF-α, IL-6, IL-8, and ER-α expression and breast cancer.

| Variable | Breast cancer / controls | OR (95% CI) | p value |
|----------|--------------------------|-------------|---------|
| Resistin | 32 / 18                  | 1.140 (0.985-1.320) | 0.078   |
| TNF-α    | 32 / 18                  | 1.169 (0.737-1.856) | 0.176   |
| IL-6     | 32 / 18                  | 1.254 (0.936-1.681) | 0.170   |
| IL-8     | 32 / 18                  | 1.082 (0.914-1.279) | 0.359   |
| ER-α     | 32 / 18                  | 1.058 (0.885-1.264) | 0.538   |

OR: Odds ratio; CI: Confidence interval; TNF-α: Tumor-necrosis factor-alpha; IL-6: Interleukin 6, IL-8: Interleukin 8; ER-α: Estrogen receptor alpha.
was detected as an important factor in the cytokine system and a major intermediate for cancer-associated inflammation [34]. TNF-α can induce tumor proliferation and can increase the invasions of breast cancer cells through the modulation of several metastasis-related genes [35,36]. Taken together, TNF-α can involve in the initiation and development of breast cancer [35].

We found the mRNA expression of IL-8 was high in breast cancer patients in comparison to controls but not significant. It has been demonstrated that serum level of IL-8 was significantly high and commonly associated with the enhanced clinical course, a higher tumor grade, and the presence of liver or lymph node involvement in high-grade breast cancer patients. [37]. The high expression of IL-8 in breast cancer cells with negative estrogen receptors can induce the high metastatic possibility of the cells [38].

Our results indicated that the mRNA expression of ER-α increased in breast cancer patients without surgery in comparison to controls but not significant; whereas, its expression significantly decreased in patients with mastectomy subgroup in comparison to patients without surgery (data not shown here). We didn't find any report regarding the effect of surgery on the mRNA expression of ER-α in PBMCs, thus, we proposed that preoperative chemotherapy causes reduction of ER-α expression. This result is consistent with the result of the study of Lee et al. [39] who found that the expression of estrogen or progesterone receptor changed in 61% of breast cancers after preoperative chemotherapy. Preoperative chemotherapy is responsible for the reduction of the primary tumor and can facilitate surgical operation. However, its effect on the expression of the estrogen receptors is not completely understood. The assessment of estrogen and progesterone receptor expression not only is well-known management for breast cancer diagnosis but also is a predictive factor for the response of hormonal adjuvant therapy [40]. Taucher et al. [41] proposed that primary chemotherapy could significantly decrease estrogen receptor (ER) and progesterone receptor (PR) levels. They also observed that, in patients with preoperative chemotherapy, the size of ER-negative primary tumors significantly increased. Others didn't find any effect of preoperative chemotherapy on the expression of estrogen receptors [42-44].

### 5. Conclusion

Our findings indicated that breast cancer especially in the early stage can affect the expression of certain genes in PBMCs. Measurement and analyze the expression of these genes have the potential to develop a PBMC-based gene-expression test for early detection of breast cancer. Moreover, according to these results, we suggest that the high expression of IL-6 in PBMCs may be considered as a new potential biomarker for the detection of breast cancer. However, further prospective and longitudinal studies are needed to evaluate whether inflammatory cytokines in PBMCs can be used as a predictive marker for the diagnosis and management of breast cancer.

### Acknowledgements/conflict of interest

This paper is issued from the thesis of Maasoumeh Zare Moaiedi, and the financial support was provided by Hyperlipidemia Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (Grant Number. HLRC-9802). The authors declare to have no conflicts of interest.

### Informed consent

All individuals who participated in the study provided their written informed consent, and the Ethics Committee of the Ahvaz Jundishapur University of Medical Sciences approved the study (Ahvaz, Iran; approval no. IR.AJUMS.MEDICINE.REC.1398.005). The research protocol was in accordance with the principles of the 1964 Declaration of Helsinki with its later amendments.

### Table 4. Diagnostic value of PBMCs biomarkers for breast cancer patients.

| Variable | AUC     | OR (95% CI) | p-value |
|----------|---------|-------------|---------|
| Resistin | 0.680   | 0.470-0.890 | 0.110   |
| IL-6     | 0.825   | 0.549-0.947 | 0.030   |
| TNF-α    | 0.514   | 0.271-0.757 | 0.908   |
| IL-8     | 0.522   | 0.254-0.793 | 0.870   |
| ER-α     | 0.700   | 0.454-0.960 | 0.110   |

AUC: Area under the ROC curve; CI: Confidence interval; TNF-α: Tumor-necrosis factor-alpha; IL-6: Interleukin 6, IL-8: Interleukin 8; ER-α: Estrogen receptor alpha.

### References

1. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiology, Biomarkers & Prevention 2017; 26 (4): 444-457. doi: 10.1158/1055-9965.EPI-16-0858

2. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obesity Reviews 2004; 5 (3):153-65. doi:10.1111/j.1467-789X.2004.00142.x
3. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR et al. The hormone resistin links obesity to diabetes. Nature 2001;409(6818):307–312. doi: 10.1038/35053000

4. Salageanu A, Tucureanu C, Lerescu L, Caras I, Pita C et al. Serum levels of adipokines resistin and leptin in patients with colon cancer. Journal of Medicine and life 2010;3(4):416–420.

5. Housa D, Vernerova Z, Heracek J, Cechak P, Rosova B et al. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression. Neoplasma 2008;55(5):442–446.

6. Hlavna M, Kohut L, Lipkova J, Bienertova-Vasku J, Dostalova Z et al. Relationship of resistin levels with endometrial cancer risk. Neoplasma 2011;58(2):124–128. doi: 10.4149/neo_2011_02_124

7. Assiri Adel-MA, Kamel Hala-FM, Hassanien Mohamed-IR. Resistin, Visfatin, Adiponectin, and Leptin: Risk of Breast Cancer in Pre- and Postmenopausal Saudi Females and Their Possible Diagnostic and Predictive Implications as Novel Biomarkers. Disease Markers 2015; 2015:253519. doi: 10.1155/2015/253519

8. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G et al. TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. European Cytokine Network 2006; 17 (3):196–201.

9. De Mello VD, Kolehmainen M, Schwab U, Mayer U, Laaksonen DE et al. Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. Metabolism 2008; 57:192–199. doi: 10.1016/j.metabol.2007.08.024

10. Kishimoto T. Interleukin-6: from basic science to medicine – 40 years in immunology. Annual Review of Immunology 2005; 23:1–21. doi: 10.1146/annurev.immunol.23.021704.115806

11. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine and Growth Factor Reviews 2002; 13(4–5):357–368. doi: 10.1016/s1359-6101(02)00027-8

12. Esquivel-Velázquez M, Ostoa-Salama P, Palacios-Arredial MJ, Nava-Castro KE, Ivonne Castro J, Morales-Montor J. The Role of Cytokines in Breast Cancer Development and Progression. Journal of Interferon and Cytokine Research 2015; 35(1): 1–21. doi: 10.1016/j.jir.2014.04.026

13. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. International Journal of Cancer 2003; 103:642-646. doi: 10.1002/ijc.10833

14. Knüpfen H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Research and Treatment 2007; 102(2):129–135. doi: 10.1007/s10549-006-9328-3

15. Todorovic-Rakovic N, Milovanovic J. Interleukin-8 in breast cancer progression. Journal of Interferon and Cytokine Research 2013; 33(10):563–570. doi: 10.1089/jir.2013.0023

16. Sparrmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6(5):447–458. doi: 10.1016/j.ccr.2004.09.028

17. Andres PJ, Illera JC, Caceres S, Diez L, Perez-Aleniza MD et al. Increased levels of interleukins 8 and 10 as findings of cancerinflammatory mammary cancer. Veterinary Immunology and Immunopathology 2013;152(3-4):245–51. doi: 10.1016/j.vetimm.2012.12.010

18. Lin Y, Huang R, Chen L, Li S, Shi Q et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. International Journal of Cancer 2004;109(4):507–515. doi: 10.1002/ijc.11724

19. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. Journal of Allergy and Clinical Immunology 1999; 103 (2 Pt 1):282–288. doi: 10.1016/s0091-6749(99)70503-8

20. McMurray RW, Ndebele K, Hardy KJ, Jenkins JK. 17-betaestradiol suppresses IL-2 and IL-2 receptor. Cytokine 2001; 14 (6):324–333. doi: 10.1006/cyto.2001.0900

21. Lee YC, Chen YJ, Wu CC, Lo S, Hou MF et al. Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecologic Oncology 2012; 125 (3):742-750. doi: 10.1016/j.ygyno.2012.02.032

22. Sharma P, Sahni NS, Tibshirani R, Skaane P, Urdal P et al. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Research 2005;7(5): R634-44. doi: 10.1186/bcr1203

23. Chen S, Liu M, Liang B, Ge S, Peng J et al. Identification of human peripheral blood monocyte gene markers for early screening of solid tumors. PLoS One 2020; 30;15(3): e0230905. doi: 10.1371/journal.pone.0230905

24. Dalamaga M, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavides E et al. Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clinical Biochemistry 2013; 46 (7-8):584-590. doi: 10.1016/j.clincbiochem.2013.01.001

25. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park) 2002; 16 (2):217-226.

26. O’Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. British Journal of Cancer 2001; 85 (4): 473-483. doi: 10.1054/bjoc.2001.1943

27. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE et al. Interleukin-6 is a potent growth factor for ER-a-positive metastatic prostate cancer: possible role in cancer progression. The FASEB Journal 2001;409(6818):307–312. doi: 10.1038/35053000

28. Hiba Q. Ali, Nadham K. Mahdi, Mohammad H. Al-Jowher. Serum levels of adipokines resistin and leptin in patients with breast cancer before and after mastectomy. Medical Journal of Islamic World Academy of Sciences 2012; 20(4): 121-129.

29. Chala E, Manes C, Iliades H, Skaragkas G, Mouratidou D et al. Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy. Hormones (Athens) 2006; 5 (2):137-146. doi: 10.14310/horm.2002.1177
30. Yokoe T, Iino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer 2000; 7 (3):187-190. doi: 10.1007/BF02967458

31. Conze D, Weiss L, Regen P S, Bhushan A, Weaver D et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Research 2001; 61(24):8851-8858.

32. Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q et al. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Research and Treatment 2012;135(3):737-747. doi: 10.1007/s10549-012-2196-0

33. Ablonska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z et al. TNF-a, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Archivum immunologiae et therapiae experimentalis (Warsz) 2001; 49 (1):63-69.

34. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-alpha in angiogenesis. The American Journal of Pathology 1992;140 (3): 539-544.

35. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W et al. TNF alpha acting on TNFRI promotes breast cancer growth via P42/P44 MAPK, JNK, Akt and NF-Kappa B-dependent pathways. Experimental Cell Research 2008; 314 (3):509-529. doi: 10.1016/j.yexcr.2007.10.005

36. Chen X, Shu Y, Li W, et al. TNF-alpha-induced metastasis gene changes in MCF-7 cells. Journal of Nanjing Medical University 2008; 22 (6):366-371. doi: 10.1016/S1007-4376(09)60008-3

37. Zuccari DA, Leonel C, Castro R, Gelaleti GB, Jardim BV et al. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochemica 2012;114(6):571–5766. doi: 10.1016/j.acthist.2011.10.007

38. Lyon DE, McCain NL, Walter J, Schubert C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nursing Research 2008;57(1):51–518. doi: 10.1097/NNR.0000280655.58266.6c

39. Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. The American Journal of Surgery 2003; 186 (4): 348-350. doi: 10.1016/s0002-9610(03)00271-x

40. Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 1999; 17 (5): 1474-1481. doi: 10.1200/JCO.1999.17.5.1474

41. Taucher S, Rudas M, Gnaut M, Thomanek K, Dubsky P et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocrine-related Cancer 2003; 10 (1): 91-98. doi: 10.1677/erc.0.0100901

42. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP et al. Effect of neoadjuvant chemotherapy on Ki-67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumors. Anticancer Research 1996; 16 (5B):3105-3110

43. Hawkins RA, Tesdale AL, Anderson ED, Levack PA, Chetty U et al. Does the estrogen receptor concentration of a breast cancer change during systemic therapy? British Journal of Cancer 1990; 61 (6): 877-880. doi: 10.1038/bjc.1990.196

44. Schneider J, Lucas R, Sanchez I, Ruibal A, Telleria A et al. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Research 2000; 20 (6B): 4373–4377.